News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ASLAN Pharmaceuticals Pte Ltd and Bristol-Myers Squibb Company (BMY) Enter Innovative Partnership to License and Develop Investigational Oncology Compound


11/3/2011 8:52:41 AM

SINGAPORE & PRINCETON, N.J.--(BUSINESS WIRE)--ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company (NYSE: BMY) today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors. This creative approach will accelerate the delivery of clinical proof-of-concept by leveraging the complementary strengths of an Asia-based drug development company and a global biopharmaceutical company.

Read at BioSpace.com
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES